Mast Cell-based Molecular Subtypes and Signature Associated with Clinical Outcome in Early-stage Lung Adenocarcinoma

Overview

Journal Mol Oncol

Specialties Molecular Biology
Oncology

Date 2020 Mar 17

PMID 32175651

Citations 34

Authors

Xuanwen Bao

Run Shi

Tianyu Zhao

Yanfang Wang

Affiliations

Soon will be listed here.

Abstract

Mast cells are a major component of the immune microenvironment in tumour tissues and modulate tumour progression by releasing pro-tumorigenic and antitumorigenic molecules. Regarding the impact of mast cells on the outcomes of patients with lung adenocarcinoma (LUAD) patient, several published studies have shown contradictory results. Here, we aimed at elucidating the role of mast cells in early-stage LUAD. We found that high mast cell abundance was correlated with prolonged survival in early-stage LUAD patients. The mast cell-related gene signature and gene mutation data sets were used to stratify early-stage LUAD patients into two molecular subtypes (subtype 1 and subtype 2). The neural network-based framework constructed with the mast cell-related signature showed high accuracy in predicting response to immunotherapy. Importantly, the prognostic mast cell-related signature predicted the survival probability and the potential relationship between TP53 mutation, c-MYC activation and mast cell activities. The meta-analysis confirmed the prognostic value of the mast cell-related gene signature. In summary, this study might improve our understanding of the role of mast cells in early-stage LUAD and aid in the development of immunotherapy and personalized treatments for early-stage LUAD patients.

Citing Articles

DeSide: A unified deep learning approach for cellular deconvolution of tumor microenvironment.

Xiong X, Liu Y, Pu D, Yang Z, Bi Z, Tian L Proc Natl Acad Sci U S A. 2024; 121(46):e2407096121.

PMID: 39514318 PMC: 11573681. DOI: 10.1073/pnas.2407096121.

Identification of the ferroptosis-related gene signature and the associated regulation axis in lung cancer and rheumatoid arthritis.

Cai B, Huang Y, Liu D, You Y, Chen N, Jie L Genes Immun. 2024; 25(5):367-380.

PMID: 39080453 DOI: 10.1038/s41435-024-00287-2.

RNA sequencing-based approaches to identifying disulfidptosis-related diagnostic clusters and immune landscapes in osteoporosis.

Zhang P, Li B, Chen H, Ge Z, Shang Q, Liang D Aging (Albany NY). 2024; 16(9):8198-8216.

PMID: 38738994 PMC: 11131997. DOI: 10.18632/aging.205813.

The significance of m6A RNA methylation regulators in diagnosis and subtype classification of HBV-related hepatocellular carcinoma.

Zang Q, Ju Y, Liu S, Wu S, Zhu C, Liu L Hum Cell. 2024; 37(3):752-767.

PMID: 38536633 DOI: 10.1007/s13577-024-01044-3.

Upregulation of POC1A in lung adenocarcinoma promotes tumour progression and predicts poor prognosis.

Li Z, Li J, Wu Z, Zhu Y, Zhuo T, Nong J J Cell Mol Med. 2024; 28(6):e18135.

PMID: 38429900 PMC: 10907829. DOI: 10.1111/jcmm.18135.

References

Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X . Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018; 24(10):1550-1558. PMC: 6487502. DOI: 10.1038/s41591-018-0136-1. View

Xu T, Le T, Liu L, Su N, Wang R, Sun B . CancerSubtypes: an R/Bioconductor package for molecular cancer subtype identification, validation and visualization. Bioinformatics. 2017; 33(19):3131-3133. DOI: 10.1093/bioinformatics/btx378. View

Couzin-Frankel J . Breakthrough of the year 2013. Cancer immunotherapy. Science. 2013; 342(6165):1432-3. DOI: 10.1126/science.342.6165.1432. View

Gabay M, Li Y, Felsher D . MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harb Perspect Med. 2014; 4(6). PMC: 4031954. DOI: 10.1101/cshperspect.a014241. View

Chung W, Eum H, Lee H, Lee K, Lee H, Kim K . Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer. Nat Commun. 2017; 8:15081. PMC: 5424158. DOI: 10.1038/ncomms15081. View

Wasiuk A, Dalton D, Schpero W, Stan R, Conejo-Garcia J, Noelle R . Mast cells impair the development of protective anti-tumor immunity. Cancer Immunol Immunother. 2012; 61(12):2273-82. PMC: 3808181. DOI: 10.1007/s00262-012-1276-7. View

Detoraki A, Staiano R, Granata F, Giannattasio G, Prevete N, De Paulis A . Vascular endothelial growth factors synthesized by human lung mast cells exert angiogenic effects. J Allergy Clin Immunol. 2009; 123(5):1142-9, 1149.e1-5. DOI: 10.1016/j.jaci.2009.01.044. View

Baram D, Vaday G, Salamon P, Drucker I, Hershkoviz R, Mekori Y . Human mast cells release metalloproteinase-9 on contact with activated T cells: juxtacrine regulation by TNF-alpha. J Immunol. 2001; 167(7):4008-16. DOI: 10.4049/jimmunol.167.7.4008. View

10.

Imada A, Shijubo N, Kojima H, Abe S . Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma. Eur Respir J. 2000; 15(6):1087-93. DOI: 10.1034/j.1399-3003.2000.01517.x. View

11.

Sinnamon M, Carter K, Sims L, LaFleur B, Fingleton B, Matrisian L . A protective role of mast cells in intestinal tumorigenesis. Carcinogenesis. 2008; 29(4):880-6. PMC: 9640162. DOI: 10.1093/carcin/bgn040. View

12.

Kurebayashi Y, Emoto K, Hayashi Y, Kamiyama I, Ohtsuka T, Asamura H . Comprehensive Immune Profiling of Lung Adenocarcinomas Reveals Four Immunosubtypes with Plasma Cell Subtype a Negative Indicator. Cancer Immunol Res. 2016; 4(3):234-47. DOI: 10.1158/2326-6066.CIR-15-0214. View

13.

Nagata M, Shijubo N, Walls A, Ichimiya S, Abe S, Sato N . Chymase-positive mast cells in small sized adenocarcinoma of the lung. Virchows Arch. 2003; 443(4):565-73. DOI: 10.1007/s00428-003-0842-y. View

14.

Li X, Li J, Wu P, Zhou L, Lu B, Ying K . Smoker and non-smoker lung adenocarcinoma is characterized by distinct tumor immune microenvironments. Oncoimmunology. 2018; 7(10):e1494677. PMC: 6169585. DOI: 10.1080/2162402X.2018.1494677. View

15.

Nordlund J, Askenase P . The effect of histamine, antihistamines, and a mast cell stabilizer on the growth of cloudman melanoma cells in DBA/2 mice. J Invest Dermatol. 1983; 81(1):28-31. DOI: 10.1111/1523-1747.ep12538356. View

16.

Tong X, OKelly J, Xie D, Mori A, Lemp N, McKenna R . Cyr61 suppresses the growth of non-small-cell lung cancer cells via the beta-catenin-c-myc-p53 pathway. Oncogene. 2004; 23(28):4847-55. DOI: 10.1038/sj.onc.1207628. View

17.

Welsh T, Green R, Richardson D, Waller D, OByrne K, Bradding P . Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol. 2005; 23(35):8959-67. DOI: 10.1200/JCO.2005.01.4910. View

18.

Newman A, Liu C, Green M, Gentles A, Feng W, Xu Y . Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015; 12(5):453-7. PMC: 4739640. DOI: 10.1038/nmeth.3337. View

19.

Takanami I, Takeuchi K, Naruke M . Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. Cancer. 2000; 88(12):2686-92. View

20.

Wang Y, Zhang Q, Gao Z, Xin S, Zhao Y, Zhang K . A novel 4-gene signature for overall survival prediction in lung adenocarcinoma patients with lymph node metastasis. Cancer Cell Int. 2019; 19:100. PMC: 6469135. DOI: 10.1186/s12935-019-0822-1. View